Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia

NCT02669758 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02669758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02669758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 20, 2016
Completion date
June 29, 2018
Enrollment
281 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia